Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

X
Trial Profile

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary) ; Orvacabtagene autoleucel (Primary) ; Corticosteroids; Cyclophosphamide; Fludarabine; Steroids; Tocilizumab
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 19 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2021 Results (n=33) assessing clinical outcomes of a cohort from phase 1 portion in patients treated prophylactically with anakinra and non-anakinra prophylaxis group presented at the 26th Congress of the European Haematology Association
    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top